Chronic Fatigue Syndrome Will Be First Of PDUFA V’s Disease Area Meetings
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is bringing an ongoing program to spur drug development for CFS and myalgic encephalomyelitis under the umbrella of the user fee program’s Patient-Focused Drug Development initiative, which calls for 20 patient-centric meetings over five years.